- Recent Funding
- Investors
- SymBiosis
SymBiosis portfolio
SymBiosis has 6 portfolio companies on record at Recent Funding, with 4 investments in the last 12 months.
About this page
It is a venture capital firm based in Bentonville, US, founded in 2021. It led 1 of the 7 rounds it joined. Its most recent investment on record is AdvanCell's $315M Series B+ round in July 2026, alongside Fidelity Management & Research Company, Morningside, Eli Lilly and 15 others. By category, its portfolio leans toward Health and bio (6) and Manufacturing and industrial (1). It has co-invested with Abingworth, Sanofi Ventures and Morningside, most often Abingworth (3 rounds).
About SymBiosis
What SymBiosis invests in
- Health and bio · 6 · 100%
- Manufacturing and industrial · 1 · 17%
- Education · 1 · 17%
SymBiosis recent investments
| Company | Round | Date | Alongside |
|---|---|---|---|
| Series B+ · $315M | Fidelity Management & Research Company, Morningside, Eli Lilly +15 | ||
| Series B+ · $67.4M | Windham Venture Partners, Wellington Management, Novartis Venture Fund +6 | ||
| Series A · $77.5M | DaVita Venture Group (lead), U.S. Renal Care, Abingworth (lead) +2 | ||
| Series B+ · $287M | SilverArc Capital, Hengdian Group, Adage Capital Management +6 | ||
| Series B+ · $112M · lead | Morningside, Abingworth (lead), Brandon Capital +3 | ||
| Series B+ · $50M | Kite Pharma, Bioluminescence Ventures, Delos Capital | ||
| Series B+ | Skyviews Life Science, Shumway Capital, Magnetar Capital (lead) +5 |
How SymBiosis invests
SymBiosis portfolio companies
AAdvanCell$315MSeries B+ · Jul 2026
FFore Biotherapeutics$67.4MSeries B+ · Jul 2026
RR1 Therapeutics$77.5MSeries A · Mar 2026
CCorxel$287MSeries B+ · Jan 2026EEnsoma$50MSeries B+ · May 2023
VVedanta BiosciencesSeries B+ · Jul 2021
| Company | Round with SymBiosis | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series B+ · $315M | $439.5M | Jul 15, 2026 Series B+ |
Health and bio |
Series B+ · $67.4M | $182.4M | Jul 8, 2026 Series B+ |
Health and bio |
Series A · $77.5M | $158M | Sep 30, 2026 Series A |
Health and bio |
Series B+ · $287M | $287M | Jan 26, 2026 Series B+ |
Health and bio |
Series B+ · $50M | $50M | May 16, 2023 Series B+ |
Health and bio |
Series B+ | $166.5M | Aug 6, 2026 round |
Most frequent co-investors
AAbingworth3 shared rounds · last Jul 15, 2026
SSanofi Ventures2 shared rounds · last Jul 15, 2026
MMorningside2 shared rounds · last Jul 15, 2026
BBrandon Capital2 shared rounds · last Jul 15, 2026
TTenmile2 shared rounds · last Jul 15, 2026
SSV Health Investors2 shared rounds · last Jul 15, 2026
SSR One2 shared rounds · last Jul 8, 2026
TT. Rowe Price1 shared round · last Jul 15, 2026
EEli Lilly1 shared round · last Jul 15, 2026
BBain Capital Life Sciences1 shared round · last Jul 15, 2026
CCatalio1 shared round · last Jul 15, 2026
- FFidelity Management & Research Company1 shared round · last Jul 15, 2026
Similar investors
AAdage Capital Management6 companies · 4 deals in 12 mo
HHealthier Capital6 companies · 4 deals in 12 mo
UUC Investments6 companies · 4 deals in 12 moHHBM Healthcare Investments6 companies · 3 deals in 12 mo
TThe FSE Group6 companies · 3 deals in 12 mo
TThird Rock Ventures6 companies · 2 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.
Share is of the 7 rounds on Recent Funding that name SymBiosis. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists SymBiosis, which is a subset of its real portfolio. API: /api/v1/investors/symbiosis (get a free API key). More: the most active VC firms and new venture capital funds.
The week's top funded startups and market insights, in your inbox every Monday.
Unsubscribe anytime · privacy